Literature DB >> 19572207

Thymidine phosphorylase as a prognostic factor in renal cell carcinoma.

Peeter Padrik1, Helgi Saar.   

Abstract

The purpose of the current study was to clarify further the clinicopathologic significance of thymidine phosphorylase (TP) expression in renal cell carcinoma (RCC). TP expression was evaluated with immunohistochemistry assays using monoclonal anti-TP antibody in formalin-fixed, paraffin-embedded archived specimens of 70 patients with radically operated nonmetastatic RCC (M0 by TNM classification). Semiquantitative analysis, using a scoring system for staining pattern and staining intensity was used. Univariate analysis showed that the characteristics that carried the prognostic significance for survival were age as continuous characteristic (chi-square log-rank test P = 0.0121), TP expression (P = 0.0061), histologic grade (P < 0.0001), and stage (P = 0.0244). In multivariate analysis (by Cox proportional hazards regression analysis), the factors significant for survival were age (HR 1.09; 95% CI 1.03-1.14), stage (HR 2.76; 95% CI 1.27-6.07), and histologic grade (HR 7.91; 95% CI 2.11-29.7), TP did not show independent significant value (HR 0.68; 95% CI 0.19-2.50). However, TP had strong correlation with histologic grade (P = 0.818). In conclusion, TP expression level in RCC is strongly correlated with histologic grade, which is one of well-known prognostic factors in RCC, but TP had no independent prognostic value.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19572207     DOI: 10.1007/s11255-009-9603-4

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  10 in total

Review 1.  The changing natural history of renal cell carcinoma.

Authors:  A J Pantuck; A Zisman; A S Belldegrun
Journal:  J Urol       Date:  2001-11       Impact factor: 7.450

2.  Thymidine phosphorylase/platelet-derived endothelial cell growth factor (PD-ECGF) associated with prognosis in renal cell carcinoma.

Authors:  K Suzuki; T Morita; S Hashimoto; A Tokue
Journal:  Urol Res       Date:  2001-02

3.  Guidelines on renal cell cancer.

Authors:  G Mickisch; J Carballido; S Hellsten; H Schulze; H Mensink
Journal:  Eur Urol       Date:  2001-09       Impact factor: 20.096

4.  Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma.

Authors:  Y Imazano; Y Takebayashi; K Nishiyama; S Akiba; K Miyadera; Y Yamada; S Akiyama; Y Ohi
Journal:  J Clin Oncol       Date:  1997-07       Impact factor: 44.544

Review 5.  Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment.

Authors:  Masakazu Toi; Mohammad Atiqur Rahman; Hiroko Bando; Louis W C Chow
Journal:  Lancet Oncol       Date:  2005-03       Impact factor: 41.316

6.  Renal cell carcinoma guideline.

Authors:  Börje Ljungberg; Damian C Hanbury; Marcus A Kuczyk; Axel S Merseburger; Peter F A Mulders; Jean-Jacques Patard; Ioanel C Sinescu
Journal:  Eur Urol       Date:  2007-03-28       Impact factor: 20.096

7.  High levels of thymidine phosphorylase as an independent prognostic factor in renal cell carcinoma.

Authors:  Tatsuya Takayama; Soichi Mugiya; Takayuki Sugiyama; Takahiro Aoki; Hiroshi Furuse; Hongming Liu; Yasuhiro Hirano; Fumitake Kai; Tomomi Ushiyama; Seiichiro Ozono
Journal:  Jpn J Clin Oncol       Date:  2006-07-22       Impact factor: 3.019

8.  Thymidine phosphorylase levels as a prognostic factor in renal cell carcinoma.

Authors:  S Wada; R Yoshimura; T Naganuma; N Yoshida; K Narita; S Ikemoto
Journal:  BJU Int       Date:  2003-01       Impact factor: 5.588

9.  The significance of thymidine phosphorylase/platelet-derived endothelial cell growth factor activity in renal cell carcinoma.

Authors:  Yoichi Mizutani; Hiromi Wada; Osamu Yoshida; Masakazu Fukushima; Akihiro Kawauchi; Masahiro Nakao; Tsuneharu Miki
Journal:  Cancer       Date:  2003-08-15       Impact factor: 6.860

10.  Expression of thymidine phosphorylase in primary human renal cell carcinoma by ELISA method.

Authors:  Hidetoshi Kinsui; Takeshi Ueda; Hiroyoshi Suzuki; Shigeo Isaka; Nobuyuki Sekita; Akira Komiya; Toyofusa Tobe; Tomonori Yamanishi; Koichiro Akakura; Tomohiko Ichikawa; Tatsuo Igarashi; Haruo Ito
Journal:  Jpn J Cancer Res       Date:  2002-03
  10 in total
  2 in total

Review 1.  The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma.

Authors:  Sunao Shoji; Mayura Nakano; Haruhiro Sato; Xian Yang Tang; Yoshiyuki Robert Osamura; Toshiro Terachi; Toyoaki Uchida; Koichi Takeya
Journal:  Clin Exp Metastasis       Date:  2014-01       Impact factor: 5.150

2.  Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy.

Authors:  Youcef M Rustum; Sreenivasulu Chintala; Farukh A Durrani; Arup Bhattacharya
Journal:  Int J Mol Sci       Date:  2018-10-29       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.